文献速递血液净化与透析肾血管病与高血压水电解质与酸碱

低钠透析液对血液透析患者组织钠蓄积影响的随机交叉试验

Randomized Crossover Trial of Low Sodium Dialysate on Tissue Sodium Accumulation in Hemodialysis.
PubMed 文献 · Kidney Int Rep · 2026-05-08

本随机交叉试验评估低钠透析液(132 mEq/l)与高钠透析液(138 mEq/l)对维持性血液透析患者皮肤和肌肉组织钠蓄积及炎症标志物的影响。28例随机分组,23例完成两种治疗;低钠透析液使肌肉钠降低0.8、皮肤钠降低1.5,均未达统计学显著性(P=0.27和0.09)。调整基线组织钠和超滤率后,低钠透析与皮肤钠降低相关;较高超滤率与皮肤和肌肉钠降低均显著相关。两组hs-CRP和前白蛋白无显著变化,无严重研究相关不良事件。

要点

  • 低钠透析液(132 mEq/l)较高钠透析液(138 mEq/l)未显著降低肌肉和皮肤组织钠。
  • 调整基线组织钠和超滤率后,低钠透析与皮肤钠降低相关,但与肌肉钠无关。
  • 较高超滤率与皮肤和肌肉组织钠降低均显著相关。

核心结论

  • 低钠透析液和超滤率均可能调节组织钠蓄积,但低钠透析液对组织钠的降低作用未达统计学显著性。
  • 需更大规模研究评估低钠透析液和高超滤率单独及联合对组织钠蓄积和临床结局的影响。

研究设计与样本

  • 随机交叉临床试验,维持性血液透析患者先接受4周低钠透析液(132 mEq/l)或高钠透析液(138 mEq/l),再交叉至另一治疗。
  • 28例随机分组,23例完成两种治疗; each治疗结束时用23Na磁共振成像评估组织钠。

主要发现

  • 从高钠到低钠透析液的组织钠最小二乘均值治疗差异:肌肉钠-0.8(P=0.27),皮肤钠-1.5(P=0.09),均未达统计学显著性。
  • 调整基线组织钠和超滤率后,低钠透析与皮肤钠降低相关,但与肌肉钠无关。
  • 较高超滤率与皮肤和肌肉钠降低均显著相关。
  • 两种治疗间hs-CRP和前白蛋白无显著变化。
  • 两种治疗期间均无严重研究相关不良事件。

临床怎么用

  • 低钠透析液(132 mEq/l)在本研究短期(4周)内安全,未出现严重研究相关不良事件。
  • 超滤率可能是影响组织钠蓄积的可调节因素,临床设定超滤目标时需综合考虑。

局限性

  • 样本量较小(28例随机,23例完成),可能不足以检测组织钠的显著差异。
  • 治疗周期较短(4周),长期效应未知。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Patients on maintenance hemodialysis (MHD) have higher tissue sodium accumulation in skin and muscle. In this randomized, crossover clinical trial, we assessed the safety and efficacy of low sodium dialysate on skin and muscle sodium accumulation, and systemic markers of inflammation. METHODS: Patients on MHD were assigned to initial treatment with either 4-weeks of low sodium dialysate (132 mEq/l) or high sodium dialysate (138 mEq/l). Tissue sodium was assessed with 23Na magnetic resonance imaging at the end of each treatment. RESULTS: Of 28 randomized participants, 23 completed both treatments. The least-squares mean treatment difference in tissue sodium from high-sodium to low-sodium dialysate were -0.8 for muscle sodium and -1.5 for skin sodium and did not reach statistical significance (P = 0.27 and 0.09, respectively). In models adjusted for baseline tissue sodium and ultrafiltration rate, low dialysate treatment was associated with decrease in skin sodium but not muscle sodium. Higher ultrafiltration rate was significantly associated with decrease in both skin and muscle sodium. No significant change was seen in high-sensitivity C-reactive protein (hs-CRP) and prealbumin between treatments. There was no serious study-related adverse event (AE) during either treatment. CONCLUSION: Our study suggests that both low-sodium dialysate and ultrafiltration rate may modify tissue sodium. Future larger studies are needed to evaluate the effects of low-sodium dialysate and high ultrafiltration rate, individually and combined on tissue sodium accumulation and clinical outcomes.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Ertuglu LA, Dilaver RG, Gamboa J, et al. Randomized Crossover Trial of Low Sodium Dialysate on Tissue Sodium Accumulation in Hemodialysis. Kidney Int Rep. 2026. PMID: 42404870. doi:10.1016/j.ekir.2026.106581

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。